We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Immune System's Response to Young Women's Breast Cancer

This study is currently recruiting participants.
Verified August 2017 by University of Colorado, Denver
ClinicalTrials.gov Identifier:
First Posted: January 2, 2012
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Colorado, Denver
This study plans to learn more about the immune system's response to breast cancer in young women.

Breast Cancer Breast Cancer and Pregnancy

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Retrospective
Official Title: A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: Throughout study participation ]
    Prospective cohort study.

Biospecimen Retention:   Samples With DNA
Tissue, Blood and urine may be collected from subjects who were recently diagnosed. Subjects who were diagnosed after treatment begins or has ended will only be eligible for tissue donation section of study

Estimated Enrollment: 800
Actual Study Start Date: July 21, 2009
Estimated Study Completion Date: July 2021
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Detailed Description:
The investigators will be looking at the level of immune suppression in different types of breast cancer. The investigators will use blood, urine, and tissue samples from patients with Pregnancy Associated Breast Cancer (PABC) versus non-PABC, as well as comparing different types of breast cancer. If tissue sampling permits, the investigators may use some of the breast cancer tissue to develop models for human cancer for drug targeting. Understanding the immune response and suppression in different types of cancer will help us understand mechanisms involved in breast cancer better and help the investigators in developing new treatment in the future.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women who are between the ages of 18 and 49 who have been diagnosed with breast cancer. Need not be in active treatment.

Inclusion Criteria:

  • Females 50 or younger
  • Histological or cytological confirmation of breast cancer
  • Any clinical stage is allowed

Exclusion Criteria:

  • Any known autoimmune condition, chronic steroid use, underlying immune disease (other than breast cancer), use of immunomodulatory prescription drugs for any medical condition.
  • The presence of other comorbid conditions known to impact immune function, (such as: type I diabetes, uncontrolled adult onset diabetes, severe chronic obstructive pulmonary disease (COPD), uncontrolled infection or known HIV infection.)
  • Underlying psychiatric condition which would, in the opinion of the investigator, preclude compliance with study requirements
  • Diagnosed with another type of cancer within 5 years except for breast cancer, cervical or non-melanomatous skin cancer.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01503190

Contact: Emily Rozzo 303-724-6077 emily.rozzo@ucdenver.edu

United States, Colorado
University of Colorado Denver Recruiting
Aurora, Colorado, United States, 80045
Contact: Emily Rozzo    303-724-6077    EMILY.ROZZO@UCDENVER.EDU   
Principal Investigator: Virginia Borges, MD, MMSc         
Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Virginia Borges, MD, MMSc University of Colorado, Denver
  More Information

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT01503190     History of Changes
Other Study ID Numbers: 09-0583.cc
First Submitted: December 29, 2011
First Posted: January 2, 2012
Last Update Posted: August 22, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Colorado, Denver:
Breast Cancer
Young Women
Pregnancy Associated Breast Cancer
Premenopausal Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases